Design Therapeutics

US · DSGN #3479 by market cap Listed 2021

11.38 -0.31 -2.65%

Live - 5344 symbols - heartbeat 96s ago · 2026-10-08 09:56

Pre-market 11.81 +1.03%

After-hours 11.69 0.00%

Market cap: 712.18M
P/E (TTM): -9.64
P/B: 3.53
EPS: -1.22
Div yield: 0.00%
52W pos: 51%

Reader sentiment Are you bullish or bearish on DSGN?

Anonymous reader poll. Unscientific, not investment advice.

About Design Therapeutics

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Founded: 2017
CEO: Dr. Pratik Shah, PhD
Employees: 54
Headquarters: Carlsbad, California, United States of America
Fiscal year end: 12-31
Website: designtx.com

Company profile

Exchange: US
Symbol: DSGN
Market-cap rank: #3479
Listing date: 2021-03-26
Market cap: 712.18M
Float cap: 411.88M
Shares out: 62.58M
Float shares: 36.19M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 09:56:28 · For reference only, not investment advice and not tailored to your situation.